Precigen Posts Additional Interim Data From Type 1 Diabetes Trial

  • Precigen Inc's PGEN subsidiary Precigen ActoBio has announced additional interim data from Phase 1b/2a study of AG019 ActoBiotics for recent-onset type 1 diabetes (T1D).
  • Related: Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes.
  • New AG019 monotherapy data showed that glycated hemoglobin (HbA1c) was below the 7% target for 100% of adult patients and 92% of the patients aged 17 years and above up to 12 months after dosing initiation. 
  • A stabilization of IDAA1c below 9 was seen in 78% of adult patients and 75% of patients aged 17 years and above up to 12 months after dosing initiation.
  • New AG019 combination therapy data show stabilization of HbA1c below the ADA target (7%) was demonstrated in 70% of adult patients up to 12 months after dosing initiation. 
  • HbA1c levels were below target in 75% of the adolescent patients up to 6 months after dosing initiation and remained below target for whom 12-month data is available. 
  • The combination therapy includes AG019 plus Provention Bio Inc's PRVB teplizumab.
  • Price Action: PGEN stock is up 0.20% at $5 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefsPhase 1 TrialPhase 2 TrialType I Diabetes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!